DA Davidson Maintains Buy on Cellebrite DI, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 57.8%

Neg 57.8% Neu 0% Pos 0%

DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.